The Phase 2 trial reference point The Phase 2 retatrutide trial (Jastreboff et al., New England Journal of Medicine 2023) enrolled 338 adults across placebo and retatrutide arms at 1, 4, 8, and 12 mg weekly
Differences between groups were assessed by one- or two-way ANOVA with time and treatment as covariants followed by Bonferronis post hoc multiple comparison testing as indicated in the figure legends
However, compounded drugs are not FDA approved, which means FDA does not review them for safety, effectiveness or quality before they are marketed
Ask your provider whether estradiol should be checked
Mounjaro is a registered trademark of Eli Lilly and Company
Diabetes 59 (11), 26972707